clinicaltrials.gov
ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted RSS plūsma
Saņem jaunākos atjauninājumus no ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted uzreiz, tiklīdz tie parādās.
Jaunākie ieraksti
Lasiet ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted tur, kur parasti lasāt
Jautājumi
Kāda ir ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted RSS plūsmas URL adrese?
Plūsmas adrese ir https://clinicaltrials.gov/api/rss?term=%28%22generalized+myasthenia+gravis%22+OR+%22myasthenia+gravis%22%29+AND+%28eculizumab+OR+ravulizumab+OR+gefurulimab+OR+inebilizumab+OR+nipocalimab+OR+zilucoplan+OR+rozanolixizumab+OR+efgartigimod+OR+remibrutinib%29&dateField=LastUpdatePostDate. Ielīmējiet to jebkurā RSS lasītājā vai noklikšķiniet uz Sekot tagad, lai lasītu to Feeder.
Cik bieži ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted publicē ierakstus?
ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted publicē ierakstus aptuveni 5 reizes nedēļā. Pēdējais ieraksts tika publicēts pirms apmēram 2 stundas.
Vai ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted RSS plūsma darbojas?
Jā. Feeder to pārbaudīja pirms 10 minūtes, un plūsma atbildēja kā parasti.
Kā sekot ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted pakalpojumā Feeder?
Noklikšķiniet uz Sekot tagad un reģistrējieties, ja jums vēl nav konta. Feeder bezmaksas plāns ietver līdz 200 plūsmām tīmeklī, iPhone un Android ierīcēs. Kredītkarte nav nepieciešama.
Sekojiet ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted pakalpojumā Feeder
Feeder bezmaksas plāns ietver līdz 200 plūsmām tīmeklī, iPhone un Android ierīcēs. Kredītkarte nav nepieciešama.